Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06830863 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate Topical ATR04-484 for EGFRi-Associated Dermal Toxicity
A Phase 1 study of EGFR Inhibitor-associated Rash, sponsored by Azitra.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
- 6
- Study locations
NCT06830863: Recruiting Phase 1 study of EGFR Inhibitor-associated Rash, sponsored by Azitra.
NCT06830863 is a Phase 1 study of EGFR Inhibitor-associated Rash that is actively recruiting participants, run by Azitra. The registered enrollment target is 32 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (47% lower). The trial reports 6 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06830863, a Phase 1 study of EGFR Inhibitor-associated Rash, is actively recruiting participants, sponsored by Azitra.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
- 6
- Study locations
Study Summary
The goal of this randomized clinical trial is to learn if topical treatment with ATR04-484 can treat skin rash in patients undergoing EGFR inhibitor (EGFRi) therapy. The primary goal of the study is to determine safety and tolerability of ATR04-484, and the secondary goal of the study is to assess efficacy signals of ATR04-484. Researchers will compare treatment of ATR04-484 to its vehicle. Participants will: * Apply ATR04-484 or vehicle daily for 28 days * Visit the clinic periodically for evaluation and sample collection
Primary Outcome
Treatment-emergent adverse events
Conditions Studied
Interventions
- DRUG Vehicle
- DRUG ATR04-484
Study Locations (6)
Arkansas
- Genesis Cancer and Blood Institute - Hot Springs
Connecticut
- Yale University School of Medicine - New Haven
New York
- NYU Langone - New York
Ohio
- The Ohio State University - Gahanna
Texas
- MD Anderson - Houston
Virginia
- Inova Schar Cancer - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2025-08-25 |
| Est. Completion | 2027-02-15 |
| Phase | Phase 1 |
What NCT06830863 shows while recruiting
NCT06830863 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (47% lower).
The record links to 1 condition, with EGFR Inhibitor-associated Rash appearing as the primary indexed condition, and to 2 interventions - of which Vehicle is the first listed.
NCT06830863 lists 6 locations in 6 states (Arkansas, Connecticut, New York).
Frequently Asked Questions
What is clinical trial NCT06830863 about?
NCT06830863 is a clinical study titled "A Study to Evaluate Topical ATR04-484 for EGFRi-Associated Dermal Toxicity". The goal of this randomized clinical trial is to learn if topical treatment with ATR04-484 can treat skin rash in patients undergoing EGFR inhibitor (EGFRi) therapy. The primary goal of the study is to determine safety and tolerability of ATR04-484, and the secondary goal of the study is to assess e...
What is the current status of trial NCT06830863?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2025-08-25. Estimated completion is 2027-02-15.
What conditions does trial NCT06830863 study?
This clinical trial studies the following conditions: EGFR Inhibitor-associated Rash.
What interventions are being tested in trial NCT06830863?
The interventions under investigation include: Vehicle (DRUG), ATR04-484 (DRUG).
Who is sponsoring clinical trial NCT06830863?
This trial is sponsored by Azitra, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06830863 being conducted?
This trial has 6 study locations across Arkansas, Connecticut, New York, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for EGFR Inhibitor-associated Rash
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06830863's enrollment target sits among peer trials
32 1296th of 2000 higher than 679 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI